Harrow, Inc. (HROW) SEC Filings & Earnings Calls

Integration risk of acquired product and personnel; milestone payments dependent on sales performance.

“Harrow expects to onboard these new colleagues during the fourth quarter of 2026.” · word for word

Competition in dry eye market; TYRVAYA faces established therapies.

“Dry eye disease is complex and multifactorial, and there is no single treatment approach that works for every patient.” · word for word

No material risk; CFO already in place.

“No additional compensation; internal reassignment.”

Operating cash flow negative

“Net cash used in operating activities during the six months ended June 30, 2026 was $18,747,000 compared to net cash provided by operating activities of $18,865,000 during the same period in the prior year.” · word for word

High debt and interest expense

“Interest expense, net, was $6,263,000 and $11,760,000 for the three and six months ended June 30, 2026” · word for word

Dependence on future financing

“We may be unable to obtain financing when necessary as a result of, among other things, our performance, general economic conditions, conditions in the pharmaceuticals and pharmacy industries, or our operating history.” · word for word

Execution risk on ambitious H2 ramp; revenue more than double H1 required to meet guidance.

“Our 2026 financial guidance implies second-half revenue of more than double what we delivered in the first half.” · word for word

IHEEZO lost pass-through reimbursement status, eliminating ASC volume overnight; recovery dependent on other channels.

“Despite losing pass-through reimbursement status on April 1, a headwind that eliminated all our ambulatory surgery center (ASC) volume virtually overnight” · word for word

TYRVAYA acquisition integration risk; deal not yet closed.

“Given the anticipated timing of the TYRVAYA transaction close and its integration into our portfolio, it should contribute to revenue in 2026.” · word for word

Acquisition may not close or may be delayed.

“there can be no assurance that the Acquisition will be completed on the anticipated timeline or at all” · word for word

Milestone payments dependent on sales performance; may not be achieved.

“payable if specified annual net sales thresholds for TYRVAYA are achieved” · word for word

Integration risk and potential failure to realize anticipated benefits.

“the anticipated benefits of the Acquisition may not be realized” · word for word

Gross-to-net pressure from new commercial coverage; temporary but impacted Q1 revenue by ~$8M.

“Higher-than-anticipated buy-down costs for these patients... created gross-to-net pressure that exceeded our internal assumptions.” · word for word

Execution risk in scaling sales force; new hires need time to become productive.

“While you may see early signs of progress in the second quarter, we expect the true impact to build meaningfully in the second half.” · word for word

Revenue concentration and gross-to-net deduction risk

“Our revenue for VEVYE decreased slightly from the three months ended March 31, 2025 as we recognized an increase in the gross-to-net revenue deductions associated with our recent coverage wins and our cash pay program.” · word for word

Operating cash flow negative

“Net cash used in operating activities during the three months ended March 31, 2026 was $8,992,000 compared to net cash provided by operating activities of $19,668,000 during the same period in the prior year.” · word for word

Concentration of insider ownership

“All executives and directors as a group own 12.80% of outstanding shares.” · word for word

Related-party transactions

“The transaction was reviewed, negotiated and approved by a special committee of the Board composed solely of independent and disinterested directors.” · word for word

Increased debt burden with 8.625% coupon, raising interest expense and leverage.

“Issuance of $50M additional 8.625% Senior Notes due 2030, increasing total debt to $300M under the indenture.”

High coupon debt (8.625%) increases interest expense and financial leverage, potentially straining cash flows.

“8.625% Senior Notes due 2030; total debt would be $300M if completed.”

Offering completion risk: no assurance that the offering will be completed on favorable terms or at all.

“There can be no assurance that the Company will be able to complete the Offering on terms and conditions favorable to it or at all.” · word for word

High coupon debt (8.625%) increases interest expense and financial leverage, potentially straining cash flows.

“8.625% Senior Notes due 2030; total debt now $300M ($250M existing + $50M new).”

Drug Pricing Pressure from IRA and State Laws

“The IRA’s drug pricing controls and Medicare redesign is likely to have a material adverse effect on our sales (particularly for our branded products that are more substantially reliant on Medicare reimbursement), our business and our results of operations.” · word for word

FDA Enforcement at Compounding Facility

“NJOF voluntarily recalled certain products and provided regular updates to the FDA regarding its remediation activities and other commitments, including Project Beagle.” · word for word

Cybersecurity Incident with Financial Loss

“In November 2024, we became aware of a cybersecurity incident that involved unauthorized access of an employee’s email account. Through this unauthorized access the threat actor was able to fraudulently divert Company funds to its bank account.” · word for word

California License Surrender Restricts Sales

“ImprimisRx voluntarily surrendered its California nonresident 503B outsourcing facility license and California nonresident 503A compounding pharmacy license. The loss of these licenses restricts our ability to sell or dispense certain compounded products in California and has reduced revenues from that state.” · word for word

Full year net loss of $5.1M despite strong revenue growth; IPR&D costs impacting GAAP profitability.

“full-year 2025 net loss of $5.1 million and Adjusted EBITDA of $61.9 million.” · word for word

Company is expanding commercial footprint, which may increase operating expenses.

“we are expanding our commercial footprint to maximize our growth potential.” · word for word

No material risks identified beyond typical execution risk on revenue milestone.

“No risk factors discussed in this filing.”

Potential dilution from future share issuance for milestone payments.

“Potential future issuance of shares in connection with Melt acquisition.”

TRIESENCE and RSP portfolio underperformance; price cut may pressure margins near-term.

“TRIESENCE® and our Rare & Specialty Products (RSP) portfolio have not met my expectations this year — including in the third quarter” · word for word

Debt Service and Refinancing Risk

“The 2030 Notes bear interest at the rate of 8.625% per annum ... We used the net proceeds from the 2030 Notes offering to prepay all then outstanding senior debt borrowings.” · word for word

Contingent Milestone Payment Risk

“Upon FDA approval of MELT-300, the Company shall pay an aggregate amount in cash of approximately $87,200,000 ... Upon achievement of various annual net sales milestones ... the Company shall make one-time cash payments that in the aggregate may total up to approximately $261,000,000.” · word for word

Gross Margin Pressure

“ImprimisRx gross margin decreased during the 2025 periods compared to the prior year period due to the previously mentioned product mix as well as one-time costs that impacted our efficiency.” · word for word